Das Produkt wurde korrekt in den Warenkorb gelegt.

discount label
H-MLLAVLYCL-OH
3D-Ansicht

Biosynth logo

H-MLLAVLYCL-OH

Ref. 3D-PP47847

1mg
217,00 €
10mg
253,00 €
100mg
455,00 €
Voraussichtliche Lieferung in Vereinigte Staaten, am Freitag 27. Dezember 2024

Produktinformation

Name:
H-MLLAVLYCL-OH
Beschreibung:

Peptide H-MLLAVLYCL-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-MLLAVLYCL-OH include the following: C. Waca–LFEL T Waca–LFEL, G WOLFF-VORBECK - Symposium in Immunology VI , 2012 - books.google.comhttps://books.google.com/books?hl=en&lr=&id=LtjnCAAAQBAJ&oi=fnd&pg=PR11&dq=(%22MLLAVLYCL%22+OR+%22H-MLLAVLYCL-OH%22)+AND+peptide&ots=mtxlsVorIl&sig=v3hILwWNe3TO_tzuyIUGVeMUvwA Shared and Individual CTL-Defined Antigens on Human Melanoma Cells T Wölfel, J Schneider , M Hauer, C Wölfel - in Immunology VI: Tumor , 1997 - Springerhttps://link.springer.com/content/pdf/10.1007/978-3-642-60562-8.pdf#page=24 Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes T Wölfel, A Van Pel, V Brichard - European journal of , 1994 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/eji.1830240340 Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma NG Chakraborty, JR Sporn, AF Tortora - Cancer Immunology , 1998 - Springerhttps://link.springer.com/article/10.1007/s002620050504 Blood T-cell Vbeta transcriptome in melanoma patients N Degauque , D Schadendorf , S Brouard - journal of cancer, 2004 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.20149 An HLA-A2 polyepitope vaccine for melanoma immunotherapy L Mateo, J Gardner, Q Chen, C Schmidt - The Journal of , 1999 - journals.aai.orghttps://journals.aai.org/jimmunol/article/163/7/4058/105313 HLA-A2 restricted, melanocyte-specific CD8+ T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against KS Lang, A Muhm, A Moris, S Stevanovic - Journal of Investigative , 2001 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0022202X1541262X Multivalent immunity targeting tumor-associated antigens by intra-lymph node DNA-prime, peptide-boost vaccination KA Smith, Z Qiu, R Wong, VL Tam, BL Tam - Cancer Gene , 2011 - nature.comhttps://www.nature.com/articles/cgt201045 Identification of a new shared HLA-A2. 1 restricted epitope from the melanoma antigen tyrosinase JP Riley, SA Rosenberg - Journal of , 2001 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2001/05000/Identification_of_a_New_Shared_HLA_A2_1_Restricted.4.aspx Molecular anatomy of tyrosinase and its related proteins: beyond the histidine-bound metal catalytic center JC Garcaca­a-Borron , F Solano - Pigment Cell Research, 2002 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1034/j.1600-0749.2002.02012.x Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma E Jager, M Ringhoffer - journal of cancer, 1997 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/(SICI)1097-0215(19970410)71:2%3C142::AID-IJC3%3E3.0.CO;2-0 Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss E Jager, M Ringhoffer, J Karbach - Journal of Cancer, 1996 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/(SICI)1097-0215(19960516)66:4%3C470::AID-IJC10%3E3.0.CO;2-C Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo E Jager, M Ringhoffer, HP Dienes - journal of cancer, 1996 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/(SICI)1097-0215(19960703)67:1%3C54::AID-IJC11%3E3.0.CO;2-C Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides E Jager, M Maeurer , H Höhn, J Karbach - journal of cancer, 2000 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/(SICI)1097-0215(20000515)86:4%3C538::AID-IJC16%3E3.0.CO;2-G The antigen processing pathway of tyrosinase, a membrane-associated melanoma protein CA Mosse - 2000 - search.proquest.comhttps://search.proquest.com/openview/9b6f30820209004e0deb5ad145369db4/1?pq-origsite=gscholar&cbl=18750&diss=y Transporter (TAP)-and proteasome-independent presentation of a melanoma-associated tyrosinase epitope C Wölfel, I Drexler, A Van Pel, T Thres - journal of cancer, 2000 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0215(20001101)88:3%3C432::AID-IJC16%3E3.0.CO;2-9 Identification and validation of viral antigens sharing sequence and structural homology with tumor-associated antigens (TAAs). C Ragone, C Manolio, B Cavalluzzo - for ImmunoTherapy of , 2021 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166618/ Immunobiology and immunotherapy of melanoma B Mukherji, NG Chakraborty - Current opinion in oncology, 1995 - journals.lww.comhttps://journals.lww.com/co-oncology/abstract/1995/03000/immunobiology_and_immunotherapy_of_melanoma.14.aspx Peptide Vaccines in Melanoma Patients A Knuth , E Jager - Symposium in Immunology VI: Tumor Immunology, 1997 - Springerhttps://link.springer.com/content/pdf/10.1007/978-3-642-60562-8.pdf#page=133 An antigenic peptide produced by reverse splicing and double asparagine deamidation A Dalet, PF Robbins, V Stroobant - Proceedings of the , 2011 - National Acad Scienceshttps://www.pnas.org/doi/abs/10.1073/pnas.1101892108 Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2. 1-restricted immune repertoire to melanoma. A Anichini , R Mortarini, C Maccalli - (Baltimore, Md.: 1950 , 1996 - journals.aai.orghttps://journals.aai.org/jimmunol/article-abstract/156/1/208/5646

Hinweis:
Unsere Produkte sind nur für Laborzwecke. Für jede andere Verwendung, bitte melden sie sich bei uns.
Marke:
Biosynth
Langzeitlagerung:
Hinweise:

Chemische Eigenschaften

MDL:
Schmelzpunkt:
Siedepunkt:
Flammpunkt:
Dichte:
Konzentration:
EINECS:
Merck:
HS-Code:

Gefahrenhinweise

UN-Nummer:
EQ:
Klasse:
H-Sätze:
P-Sätze:
Flugverbot:
Gefahrenhinweis:
Verpackungsgruppe:
LQ:

Technische Anfrage zu: 3D-PP47847 H-MLLAVLYCL-OH

Bitte verwenden Sie stattdessen den Warenkorb, um ein Angebot oder eine Bestellung anzufordern

Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.

* Obligatorische felder
Willkommen bei CymitQuimica!Wir verwenden Cookies, um Ihren Besuch zu verbessern. Wir schließen Werbung nicht ein.

Bitte beachten Sie unsere Cookie-Richtlinie  für weitere Details oder passen Sie Ihre Einstellungen unter “Konfigurieren” an.